504-33-6 Usage
Uses
Used in Neurobiological Research:
DL-Homocysteic acid is used as a neurobiological research tool for studying the effects of oxidative stress on the developing brain. Its ability to induce oxidative stress in immature rats makes it a valuable compound for investigating the mechanisms underlying neurodegenerative diseases and potential therapeutic interventions.
Used in Chemical Synthesis:
DL-Homocysteic acid is used as a starting material or intermediate in the synthesis of various organic compounds and pharmaceuticals. Its ability to form complexes with metal ions can be exploited in the development of new chemical processes and products.
Used in Toxicology Studies:
DL-Homocysteic acid is used as a toxicological agent in studies aimed at understanding the effects of oxidative stress on biological systems. By examining the impact of DL-Homocysteic acid on immature rats, researchers can gain insights into the potential toxic effects of similar compounds and develop strategies for mitigating their harmful effects.
Check Digit Verification of cas no
The CAS Registry Mumber 504-33-6 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,0 and 4 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 504-33:
(5*5)+(4*0)+(3*4)+(2*3)+(1*3)=46
46 % 10 = 6
So 504-33-6 is a valid CAS Registry Number.
InChI:InChI=1/C4H9NO5S/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H,8,9,10)/p-1/t3-/m0/s1
504-33-6Relevant academic research and scientific papers
GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS
-
, (2010/08/07)
Modified glucagon peptides are disclosed having improved solubility while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.
GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS
-
, (2010/08/07)
Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).
